[go: up one dir, main page]

WO2010009065A3 - Amphipathic peptide compositions - Google Patents

Amphipathic peptide compositions Download PDF

Info

Publication number
WO2010009065A3
WO2010009065A3 PCT/US2009/050443 US2009050443W WO2010009065A3 WO 2010009065 A3 WO2010009065 A3 WO 2010009065A3 US 2009050443 W US2009050443 W US 2009050443W WO 2010009065 A3 WO2010009065 A3 WO 2010009065A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide compositions
amphipathic peptide
target compound
compositions
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/050443
Other languages
French (fr)
Other versions
WO2010009065A9 (en
WO2010009065A2 (en
Inventor
Jeremy Baryza
Andrew Geall
Sushma Kommareddy
Jennifer Philips
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of WO2010009065A2 publication Critical patent/WO2010009065A2/en
Publication of WO2010009065A9 publication Critical patent/WO2010009065A9/en
Anticipated expiration legal-status Critical
Publication of WO2010009065A3 publication Critical patent/WO2010009065A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Dispersion Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present application pertains to a composition, comprising - amphipathic peptides; - lipids and - at least one target compound. Respective compositions are suitable for target compound transport and delivery, for example for systemic or local delivery to a mammal. Also provided are pharmaceutical compositions, comprising respective compositions.
PCT/US2009/050443 2008-07-15 2009-07-14 Amphipathic peptide compositions Ceased WO2010009065A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8079208P 2008-07-15 2008-07-15
US61/080,792 2008-07-15

Publications (3)

Publication Number Publication Date
WO2010009065A2 WO2010009065A2 (en) 2010-01-21
WO2010009065A9 WO2010009065A9 (en) 2010-03-11
WO2010009065A3 true WO2010009065A3 (en) 2011-01-27

Family

ID=41343337

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/050443 Ceased WO2010009065A2 (en) 2008-07-15 2009-07-14 Amphipathic peptide compositions

Country Status (1)

Country Link
WO (1) WO2010009065A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301993B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides encoding apoptosis inducing factor 1

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110200582A1 (en) 2009-12-23 2011-08-18 Novartis Ag Lipids, lipid compositions, and methods of using them
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3590949B1 (en) 2010-10-01 2022-05-18 ModernaTX, Inc. Ribonucleic acids containing n1-methyl-pseudouracils and uses thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
CN103906527B (en) 2011-06-08 2020-07-10 川斯勒佰尔公司 Lipid Nanoparticle Compositions and Methods for mRNA Delivery
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RS62993B1 (en) 2011-10-03 2022-03-31 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
AU2012352180A1 (en) 2011-12-16 2014-07-31 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EA201590683A1 (en) 2012-11-20 2015-11-30 Глаксосмитклайн Байолоджикалс С.А. RSV F TRIMMERS PRECEDING THE MERGER
PL2922554T3 (en) 2012-11-26 2022-06-20 Modernatx, Inc. Terminally modified rna
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CN105980401A (en) 2013-10-03 2016-09-28 现代治疗公司 Polynucleotides encoding low density lipoprotein receptor
SG11201608798YA (en) 2014-04-23 2016-11-29 Modernatx Inc Nucleic acid vaccines
EP2974739A1 (en) 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
CN106794141B (en) 2014-07-16 2021-05-28 诺华股份有限公司 Methods of Encapsulating Nucleic Acids in Lipid Nanoparticle Hosts
EP3169693B1 (en) 2014-07-16 2022-03-09 ModernaTX, Inc. Chimeric polynucleotides

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004080406A2 (en) * 2003-03-07 2004-09-23 Alnylam Pharmaceuticals Therapeutic compositions
WO2007145659A1 (en) * 2005-11-10 2007-12-21 The Regents Of The University Of California Synthetic ldl as targeted drug delivery vehicle

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004080406A2 (en) * 2003-03-07 2004-09-23 Alnylam Pharmaceuticals Therapeutic compositions
WO2007145659A1 (en) * 2005-11-10 2007-12-21 The Regents Of The University Of California Synthetic ldl as targeted drug delivery vehicle

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BARR I G ET AL: "ISCOMs (immunostimulating complexes): the first decade", IMMUNOLOGY AND CELL BIOLOGY, CARLTON, AU LNKD- DOI:10.1038/ICB.1996.2, vol. 74, no. 1, 1 February 1996 (1996-02-01), pages 8 - 25, XP002128950, ISSN: 0818-9641 *
FERNANDO G J P ET AL: "Peptide polymerisation facilitates incorporation into ISCOMs and increases antigen-specific IgG2a production", VACCINE, ELSEVIER LTD, GB LNKD- DOI:10.1016/0264-410X(95)00029-Z, vol. 13, no. 15, 1 January 1995 (1995-01-01), pages 1460 - 1467, XP004057459, ISSN: 0264-410X *
MEADE ET AL: "Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL LNKD- DOI:10.1016/J.ADDR.2007.03.004, vol. 59, no. 2-3, 30 March 2007 (2007-03-30), pages 134 - 140, XP022087320, ISSN: 0169-409X *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301993B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides encoding apoptosis inducing factor 1

Also Published As

Publication number Publication date
WO2010009065A9 (en) 2010-03-11
WO2010009065A2 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
WO2010009065A3 (en) Amphipathic peptide compositions
WO2010009277A3 (en) Immunogenic amphipathic peptide compositions
WO2008128775A3 (en) Stabilised pharmaceutical composition containing pregabaline
WO2008036929A3 (en) Complex for transferring an anionic substance into a cell
WO2008008364A3 (en) Enhanced stability phenylephrine liquid compositions
IL214996A (en) Isolated antibody that binds a bmca polypeptide, a pharmaceutical composition comprising the same and uses thereof
FR2941231B1 (en) NOVEL PEPTIDES, COMPOSITIONS COMPRISING THEM AND COSMETIC AND DERMO-PHARMACEUTICAL USES
WO2010065709A3 (en) Hydroxamic acid derivatives, preparation and therapeutic uses thereof
WO2009026233A3 (en) Self assembling peptide systems and methods
WO2009144481A3 (en) Peptide conjugates for delivery of biologically active compounds
AU2007299727A8 (en) Self preserved aqueous pharmaceutical compositions
WO2006084164A3 (en) Gastric retention and controlled release delivery system
BR112012003800A2 (en) composition, peptide, and pharmaceutical formulation.
WO2009062746A3 (en) Topical drugs for use in antifungal therapy
IL213748A (en) Cell adhesion inhibiting peptides, compositions comprising the same and uses thereof
WO2008093058A3 (en) Peptides and their use
WO2008142569A3 (en) Topical compositions containing magaldrate
WO2011002422A3 (en) Solubility enhancing pharmaceutical formulation
WO2012087051A3 (en) Microparticles containing physiologically active peptide, method for preparing the same, and pharmaceutical composition comprising the same
WO2008152398A3 (en) Formulations for inhalation
WO2010072341A3 (en) Agrochemical auxiliary compositions
IL192824A (en) Peptidic compounds, pharmaceutical compositions comprising them and uses thereof
WO2007075794A3 (en) Oral formulations comprising tigecycline
WO2009108713A3 (en) Topical compositions and methods utilizing peptides containing lipid-modified cysteine-containing peptides
FR2941232B1 (en) NOVEL PEPTIDES, COMPOSITIONS COMPRISING THEM AND COSMETIC AND DERMO-PHARMACEUTICAL USES

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09790354

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09790354

Country of ref document: EP

Kind code of ref document: A2